Blaine T. Davis Net Worth

The estimated Net Worth of Blaine Davis is at least $638 mil dollars as of 22 September 2020. Mr Davis owns over 1,481 units of Protara Therapeutics Inc stock worth over $2,518 and over the last 5 years he sold TARA stock worth over $0. In addition, he makes $635,310 as CFO e Principal Financial & Accounting Officer and Sec. at Protara Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Davis TARA stock SEC Form 4 insiders trading

Mr has made over 1 trades of the Protara Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 1,481 units of TARA stock worth $25,044 on 22 September 2020.

The largest trade he's ever made was buying 1,481 units of Protara Therapeutics Inc stock on 22 September 2020 worth over $25,044. On average, Mr trades about 247 units every 0 days since 2020. As of 22 September 2020 he still owns at least 1,481 units of Protara Therapeutics Inc stock.

You can see the complete history of Mr Davis stock trades at the bottom of the page.

Mr. Blaine T. Davis biography

Blaine T. Davis is the CFO, Principal Financial & Accounting Officer and Sec. at Protara Therapeutics Inc.

What is the salary of Mr Davis?

As the CFO e Principal Financial & Accounting Officer and Sec. of Protara Therapeutics Inc, the total compensation of Mr Davis at Protara Therapeutics Inc is $635,310. There are 1 executives at Protara Therapeutics Inc getting paid more, with Jesse Shefferman having the highest compensation of $1,255,836.

How old is Mr Davis?

Mr Davis is 47, he's been the CFO e Principal Financial & Accounting Officer and Sec. of Protara Therapeutics Inc since . There are 8 older and 5 younger executives at Protara Therapeutics Inc. The oldest executive at Protara Therapeutics Inc is Roger Garceau, 66, who is the Independent Director.

What's Mr Davis's mailing address?

Blaine's mailing address filed with the SEC is C/O SELECTA BIOSCIENCES, INC., 65 GROVE STREET, WATERTOWN, MA, 02472.

Insiders trading at Protara Therapeutics Inc

Over the last 5 years, insiders at Protara Therapeutics Inc have traded over $3,287,540 worth of Protara Therapeutics Inc stock and bought 250,034 units worth $1,947,929 . The most active insiders traders include Management Inc. Opaleye, Richard S Levy, eGregory Sargen. On average, Protara Therapeutics Inc executives and independent directors trade stock every 35 days with the average trade being worth of $34,731. The most recent stock trade was executed by Management Inc. Opaleye on 9 September 2024, trading 61,992 units of TARA stock currently worth $114,065.

What does Protara Therapeutics Inc do?

protara therapeutics, inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. the company's lead program is tara-002, an investigational cell therapy for the treatment of lymphatic malformations. it also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. the company was formerly known as artara therapeutics, inc. and changed its name to protara therapeutics, inc. in may 2020. protara therapeutics, inc. is based in new york, new york.

Complete history of Mr Davis stock trades at Selecta Biosciences Inc e Protara Therapeutics Inc

Protara Therapeutics Inc executives and stock owners

Protara Therapeutics Inc executives and other stock owners filed with the SEC include:

• Jesse Shefferman,
  Co-Founder, CEO, Pres & Director
• Blaine T. Davis,
  CFO, Principal Financial & Accounting Officer and Sec.
• Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D.,
  Chief Scientific Operations Officer
• Jesse Shefferman,
  President, Chief Executive Officer, Director
• Jacqueline Zummo,
  Senior Vice President - Research Operations
• Luke Beshar,
  Chairman of the Board
• Roger Garceau,
  Independent Director
• Michael Solomon,
  Independent Director
• Gregory Sargen,
  Independent Director
• Richard Levy,
  Independent Director
• Barry Flannelly,
  Director
• Blaine Davis,
  Chief Financial Officer
• Kristine Rosse,
  Sr. VP & Chief People Officer
• Justine O'Malley,
  Sr. VP of Investor Relations & Corp. Affairs
• Hannah Fry,
  Principal Accounting Officer & Controller
• Mary J. Grendell,
  Corp. Sec.
• Dr. Jathin Bandari M.D.,
  Interim Chief Medical Officer, VP & Head of Clinical Devel.
• Dr. Martin Sebastian Olivo M.D.,
  Chief Medical Officer
• Management Inc. Opaleye,
  10% owner
• Scott Braunstein,
  Director
• L.P. Opaleye,,
  10% owner
• Randall Marshall,
  
• Hannah Fry,
  VP, Controller
• Julio Casoy,
  Chief Medical Officer
• Martin Sebastian Olivo,
  Chief Medical Officer
• Jathin Bandari,
  Chief Medical Officer
• Patrick Fabbio,
  Chief Financial Officer
• Cynthia Smith,
  
• Jane Huang,